Few of the individuals who experience an opioid-related overdose had received treatment for opioid use disorder.
Mental health, education level, and recent drug use may be associated with duration of treatment with extended-release naltrexone for opioid dependence.
Euphoria associated with the stimulant methylphenidate may be mitigated by co-administration of naltrexone in patients with attention-deficit/hyperactivity disorder.
A longer duration of extended-release naltrexone treatment in individuals with opioid dependence was associated with improved outcomes and reduced rates of relapse.
All 3 opioid-dependence pharmacotherapies — methadone, buprenorphine, and oral naltrexone — were associated with reductions in inpatient substance abuse treatment.
Compared with buprenorphine-naloxone, use of extended-release naltrexone maintained abstinence from heroin and other illicit substances at a similar rate.
Early pharmacologic intervention for opioid use disorder after diagnosis is crucial to prevent relapse and overdose in adolescents and young adults.
Policies have helped make naloxone more available, thus contributing to the reduction of opioid-related deaths in the U.S.
An 8-day detoxification process using low-dose oral naltrexone showed superior efficacy to the standard 15-day approach that uses an agonist taper leading to induction with extended-release naltrexone
Clinical Pain Advisor Articles
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Reviewing the Efficacy of Invasive Procedures for Chronic Back, Knee Pain
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Lower Weighting of Hand Cortical Representations in CRPS
- Predicting Success of Focal Nerve Surgery Based on Diagnostic Block Response
- Aetna-CVS Merger Approved
- FDA Announces Draft Guidance for Consumer OTC Access to Previously Prescription Drugs
- Maryland Legislature: Will Federal Courts Permit State Regulation of Drug Prices?